Literature DB >> 29319922

The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer.

Judith Bosschieter1, R Jeroen A van Moorselaar1, André N Vis1, Tessa van Ginkel1, Birgit I Lissenberg-Witte2, Goedele M A Beckers1, Jakko A Nieuwenhuijzen1.   

Abstract

OBJECTIVE: To investigate whether the timing of an immediate instillation of mitomycin C (on the day of transurethral resection of bladder tumour [TURBT] or 1 day later) has an impact on time to recurrence of non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: All patients with NMIBC who were enrolled in a prospective trial between 1998 and 2003, and treated with an early mitomycin C instillation (on the day of TURBT or 1 day later), were selected. Statistical analysis was performed with Kaplan-Meier curves and multivariable Cox regression.
RESULTS: Administering an instillation of mitomycin C on the day of TURBT or 1 day later did not show a statistically significant difference in time to recurrence in a univariable model (log-rank P = 0.99). After correcting for the number of scheduled adjuvant instillations, no statistically significant difference could be detected either: hazard ratio 1.05 (95% confidence interval 0.81-1.35, P = 0.74).
CONCLUSION: These data do not support the hypothesis that a very early instillation (on the day of TURBT) of mitomycin C decreases the risk of recurrence as compared with an early instillation (1 day after TURBT).
© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  intravesical chemotherapy; mitomycin C; urinary bladder neoplasms

Mesh:

Substances:

Year:  2018        PMID: 29319922     DOI: 10.1111/bju.14124

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  3 in total

1.  An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?

Authors:  Judith Bosschieter; R Jeroen A van Moorselaar; Jakko A Nieuwenhuijzen
Journal:  Transl Androl Urol       Date:  2019-07

Review 2.  Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.

Authors:  Adithya Balasubramanian; Ashray Gunjur; Andrew Weickhardt; Nathan Papa; Damien Bolton; Nathan Lawrentschuk; Marlon Perera
Journal:  World J Urol       Date:  2022-01-27       Impact factor: 4.226

3.  Efficacy of compound aluminum sulfate injection as a monotherapeutic regimen in non-muscle invasive bladder cancer patients: a retrospective single-arm cohort study.

Authors:  Guanren Zhao; Fei Yang; Qi Yang; Yalong Yang; Axiang Xu; Yonghe Chen; Chunxi Wang; Lindong Du; Baofa Hong; Lei Zhang; Wenying Wang; Yuchuan Hou; Xiaoqing Wang; Xinyuan Tong; Xiaoxiong Wang; Fenghua Xu
Journal:  Transl Androl Urol       Date:  2022-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.